According to a recent study published in Journal Expert Review of Neurotherapeutics, PGB-CR (Pregabalin controlled-release) shows similar safety and efficacy as PGB-IR (Pregabalin immediate-release). Fibromyalgia (FM) is a condition that involves fatigue, cognitive impairment, musculoskeletal pain and sleep disturbances. Due to these problems, this disease dramatically affects the occupational, social and personal life. The pregabalin is an anticonvulsant and antidepressants; milnacipran and duloxetine are the FDA approved drugs for FM treatment.